ICL670 oral iron chelator: Phase II

Nine-month data from 63 evaluable patients in an open-label Phase II trial in 71 patients showed that 20 mg of ICL670 gave a 26.3% reduction in LIC vs. a 13.9% reduction for patients receiving infusio...